451473-18-0

Basic information

• Product Name: Benzoic acid, 4-[[1,4-dihydro-1-methyl-2,4-dioxo-6-(phenylethynyl)-3(2H)-quinazolinyl] methyl]-
• CAS NO: 451473-18-0
• Molecular Formula: C25H18N2O4
• Molecular Weight: 410.429
• Mol File: 451473-18-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-[[1,4-dihydro-1-methyl-2,4-dioxo-6-(phenylethynyl)-3(2H)-quinazolinyl] methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-[[1,4-dihydro-1-methyl-2,4-dioxo-6-(phenylethynyl)-3(2H)-quinazolinyl] methyl]-(451473-18-0)
• EPA Substance Registry System: Benzoic acid, 4-[[1,4-dihydro-1-methyl-2,4-dioxo-6-(phenylethynyl)-3(2H)-quinazolinyl] methyl]-(451473-18-0)

Safety Data

• Hazardous Substances Data: 451473-18-0(Hazardous Substances Data)

Upstream product

• 7087-68-5 N-ethyl-N,N-diisopropylamine 
• 536-74-3 phenylacetylene 

Relevant articles and documents

Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib

The invention provides a combination, comprising an allosteric alkyne inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric alkyne inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric alkyne inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib, and a pharmaceutically acceptable carrier, diluent, or excipient. This invention also provides a combination comprising an NSAID, or a pharmaceutically acceptable salt thereof, and an allosteric alkyne inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric alkyne inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with an NSAID, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-1 or cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric alkyne inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with an NSAID, or a pharmaceutically acceptable salt thereof. The invention combinations may also be further combined with other pharmaceutical agents depending on the disease being treated.

Alkynylated fused ring pyrimidine compounds

A compound selected from those of formula (I): wherein W1 represents O, S, or —NR3 in which R3 represents hydrogen, alkyl, OH or CN; W2 represents a group selected from hydrogen, CF3, NH2,